Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of Voriconazole eye drops
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Xingqi Pharmaceutical announced that the company's developed voriconazole eye drops completed the enrollment of the first subject today, officially entering Phase II clinical trials. The Phase II clinical trial study of voriconazole eye drops is a randomized, positive-controlled, multi-center exploratory trial aimed at preliminarily exploring the efficacy and safety of voriconazole eye drops in subjects with fungal keratitis, in order to explore safe and effective drug concentrations for Phase III clinical trials
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments